Home Companies Catalysts Deep Dives
Trulicity dulaglutide APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2014-09-18
US LOE2027-09-01
Peak Sales Est$7000M
Formulations[{"id":"trulicity-sc","doses":"0.75mg, 1.5mg, 3mg, 4.5mg pen","route":"SC","setting":"PATIENT_SELF",
Companies
LLY (ORIGINATOR)100%
Mechanism: GLP-1 agonist
Expert: Glucagon-like peptide-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via central mechanisms.
Everyday: Mimics a gut hormone that makes you feel full and helps control blood sugar. Used for diabetes and weight loss.
Targets: ["GLP-1"]
Revenue History
PeriodRevenue ($M)
Q3 2024$1,400M
2024$5,800M
2023$7,100M
Programs (1)
IndicationStageKey StudyRegional Status
Type 2 DiabetesAPPROVEDAWARD[{"stage":"APPROVED","region":"US","approval_date":"2014-09-18"},{"stage":"APPRO
Notes
Legacy GLP-1, declining as patients switch to tirzepatide
Data from Supabase · Updated 2026-03-24